Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey

Código QR

Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey

Jose Manuel Olivares,1 Manickam Thirunavukarasu,2 Jayashri Kulkarni,3 Hong Yan Zhang,4 Mingyuan Zhang,5 Fan Zhang61Department of Psychiatry, Hospital Meixoeiro, Complejo Hospitalario Universitario de Vigo, Vigo, Spain; 2Department of Psychiatry, SRM Medical College Hospital and Research Center, Tami...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Olivares JM, Thirunavukarasu M, Kulkarni J, Zang HY, Zhang M, Zhang F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/42315c7a80a645be9ceb5a2651663b86
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louz&atilde; M, et al.
Publicado: (2011)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka M, et al.
Publicado: (2015)

Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey
por: Liu CH, et al.
Publicado: (2018)

The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
por: Hashimoto K, et al.
Publicado: (2014)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists
por: Correll CU, et al.
Publicado: (2019)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
por: Xinhua&nbsp;S Ren, et al.
Publicado: (2009)

Tackling nonadherence in psychiatric disorders: current opinion
por: Farooq S, et al.
Publicado: (2014)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Hong Liu-Seifert, et al.
Publicado: (2009)

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia
por: Wu X, et al.
Publicado: (2014)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang FD, et al.
Publicado: (2017)

The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study
por: Gro&scaron;ić V, et al.
Publicado: (2014)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang X, et al.
Publicado: (2019)

Altered heart rate dynamics associated with antipsychotic-induced subjective restlessness in patients with schizophrenia
por: Kim JH, et al.
Publicado: (2013)

Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics
por: Takahiko Nagamine
Publicado: (2008)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012)

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2021)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari S, et al.
Publicado: (2015)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa T, et al.
Publicado: (2011)

Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval
por: Okayasu H, et al.
Publicado: (2021)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini F, et al.
Publicado: (2019)

Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
por: Rachael K. Blackman, et al.
Publicado: (2022)

Attitudes of psychiatrists toward obsessive–compulsive disorder patients
por: Kusalaruk P, et al.
Publicado: (2015)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
por: Li N, et al.
Publicado: (2018)

Different Attitudes of Patients and Psychiatrists Toward Benzodiazepine Treatment
por: Kawamata Y, et al.
Publicado: (2021)

The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy
por: Lisa A. Page, et al.
Publicado: (2021)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi T, et al.
Publicado: (2014)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials
por: Michel Sabe, et al.
Publicado: (2021)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic M, et al.
Publicado: (2018)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Stephan Hjorth, et al.
Publicado: (2021)

Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
por: Fan L, et al.
Publicado: (2021)

Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
por: Takeshima M, et al.
Publicado: (2018)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Takahashi M, et al.
Publicado: (2012)

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first- episode or multi-episode schizophrenia
por: Washida K, et al.
Publicado: (2013)